Line of Research - Musculoskeletal Regenerative Medicine


In the field of orthopaedic surgery, a growing interest is rising toward new, bone-substitute biomaterials. Many kinds of calcium-phosphate-based bone cements have been developed, and several addictives have been utilized to improve their bio-compatibility and bio-activity. A new bone cement, based on calcium-phosphate enriched with gelatin (GEL-CP), has been developed and is showing better mechanical properties than control cement (C-CP). The significant improvement of the cellular response, due to the presence of gelatin, suggests that the new bio-mimetic compound presents suitable characteristics to be tested in vivo and to confirm its utilization as a bone substitute, also in case of osteopenia. Compound materials based on hydroxylapatite (HA), reproducing the structure and the properties of natural mineralized tissues, are of great interest for the reparation of the bone tissue. The direct synthesis of HA nanocrystals, together with acidic amino acids, as the aspartic ac. (HA-ASP) and the glutamic ac. (HA-GLU) has been conducted in the presence of different amino acid concentrations. The results obtained in this phase of the study indicate that the presence of acidic amino acids has a positive influence on both the osteoblasts activation and the mineralization processes of the extra-cellular matrix; this finding supports further research phases, both in vitro and in vivo, preliminary to the possible clinical utilization of the compound biomaterial in orthopedics and traumatology.


The research line pursuits the following objectives:

  • Preclinical evaluation of characteristics of biocompatibility, tissue integration and capability to produce proliferative and/or differentiative responses in innovative micro and nano-structured materials;
  • Identification of procedures capable of improving the efficiency of growth factors released by platelet derivates, in the induction to differentiation of mesenchymal osteogenic and cartilaginous precursors;
  • Clinical validation of regenerative medicine methodologies based on the combined utilization of growth factors, stem cells and scaffolds;
  • Progressive reduction of invasiveness in surgical procedures (from arthrotomy to arthroscopy) in the use of scaffolds and in cell therapy;
  • Utilization of “one step” surgical procedures to utilize the enriched medullary cell component, as an alternative to techniques of in vitro expansion held at an authorized cell factory;
  • Finalization of bi-functional biomaterials to favor the simultaneous reparation of the bone and the cartilaginous tissue, for the treatment of osteochondral lesions.
Content updated 05/01/2015 - 17:46
Content edited by: Dott. Andrea Paltrinieri (
Utilizza SharethisShareThis  Scrivi una email  Vai a facebook  Vai a twitter